106PAntiproliferative effect of trastuzumab and nimotuzumab with EGF on breast cancer cells MCF-7

Background: In this study, we addressed antiproliferative effects of trastuzumab (Herceptin^®) and nimotuzumab (Theraloc^®) in a combined application with EGF on MCF-7 cells. The epidermal growth factor (EGF) receptors have been found to be implicated in the ontology and maintenance of tumor tissues, which has fostered the discovery and development of molecularly targeted anti-EGF-receptor therapies. However, the accessibility of chemotherapeutic preparations and humanized antibodies to tumor cells in the G0 phase of the cell cycle is lower than to the cells of theproliferative pool. Given this, antitumor efficiency can potentially be enhanced by synchronizing cells in the proliferative pool. To explore this opportunity, we added EGF to tumor cells in combination with nimotuzumab and trastuzumab (antibodies against EGF-R typeI and II, respectively).

http://ift.tt/2FcVdbY